Nektar Therapeutics stock faces a cash runway into 2028

Nektar Therapeutics stock (ISIN US6402683063) was last at USD 40.20 on Nasdaq on October 7, 2026, while the clinical-stage biotech continues to fund its autoimmune pipeline with a projected cash balance of USD 815 million to USD 840 million at year-end 2026. The next investor question is whether that runway can carry rezpegaldesleukin through its pivotal development plans.

Quarterly loss beats expectations

According to MarketBeat, Nektar reported second-quarter 2026 EPS of negative USD 1.23 against a consensus loss of negative USD 1.97, a USD 0.74 improvement versus expectations. Quarterly revenue was USD 10.13 million, compared with consensus revenue of USD 10.43 million.

The earnings mix remains development-heavy. The company reported a second-quarter net loss of USD 40.6 million, while non-cash royalty revenue totaled USD 10.1 million, according to Yahoo Finance. The loss figure is more than four times the quarterly royalty revenue, keeping cash preservation central to the stock story.

Rezpegaldesleukin remains central

Nektar's October 1, 2026 filing described Phase 2b REZOLVE-AA data in which 63 percent of responders maintained a SALT Score of 20 or less six months after treatment ended. The same filing said 19 percent reached a SALT Score of 10 or less after six months, versus 7 percent at Week 52, according to the SEC.

The development schedule is extended: the company plans to begin the 850-patient ZENITH AA Phase 3 study in early 2027, while a third Phase 3 atopic dermatitis study has started. That timeline makes the stated cash range a more important valuation input than near-term revenue.

Analysts see a wide valuation gap

MarketBeat lists a Moderate Buy consensus from 13 analysts with an average price target of USD 138.50. The target lies 244.5 percent above the USD 40.20 Nasdaq price, a gap that reflects the binary nature of clinical-stage valuation rather than established commercial earnings.

Nektar's market capitalization was USD 1.2 billion as of October 7, 2026. Its 52-week range was USD 33.40 to USD 109.00, placing the last price USD 6.80 above the yearly low and USD 68.80 below the yearly high.

More news and analyses on Nektar Therapeutics stock